| Species |
Human |
| Protein Construction |
NKp46/NCR1/CD335 (Gln22-Asn255)_x000D_
Accession # O76036-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized NKp46/NCR1/CD335 hFc Chimera, Human at 0.5μg/ml (100μl/well) on the plate can bind Biotinylated AntiNkp46 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
53.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 68-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
NKp46, along with NKp30 and NKp44, are activating receptors that have been collectively termed the natural cytotoxicity receptors (NCR).These receptors lack significant sequence homology to one another. They are expressed almost exclusively by NK cells and play a major role in triggering some of the key lytic activities of NK cells. |
| Synonyms |
CD335; Ly94; NCR1; NKp46; MAR-1; NKP46FLJ99094 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
